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Coronary heart disease (CHD) accounts for half of the 1 million deaths annually ascribed to cardiovascular disease
and for almost all of the 1.5 million acute myocardial infarctions. Within families affected by early and apparently
heritable CHD, dyslipidemias have a much higher prevalence than in the general population; 20%-30% of early
familial CHD has been ascribed to primary hypoalphalipoproteinemia (lowHDL-C). This study assesses the evidence
for linkage of low HDL-C to chromosomal region 11q23 in 105 large Utah pedigrees ascertained with closely
related clusters of early CHD and expanded on the basis of dyslipidemia. Linkage analysis was performed by use
of 22 STRP markers in a 55-cM region of chromosome 11. Two-point analysis based on a general, dominant-
phenotype model yielded LODs of 2.9 for full pedigrees and 3.5 for 167 four-generation split pedigrees. To deﬁne
a localization region, model optimization was performed using the heterogeneity, multipoint LOD score (mpHLOD).
This linkage deﬁnes a region on 11q23.3 that is ∼10 cM distal to—and apparently distinct from—the ApoAI/CIII/
AIV gene cluster and thus represents a putative novel localization for the low HDL-C phenotype.
Introduction
Cardiovascular disease remains the most common cause
of death in the United States, accounting for nearly one
third of all mortality. Coronary artery disease (CAD) or
coronary heart disease (CHD) accounts for half of the
1 million deaths annually ascribed to cardiovascular dis-
ease and for almost all of the 1.5 million acute myo-
cardial infarctions. Studies of early CHD sib pairs have
identiﬁed several risk factors that contribute to CHD,
including family history, obesity, smoking, diabetes, hy-
pertension, dyslipidemia, and physical inactivity (Gold-
stein et al. 1973; Williams et al. 1990).
Within families having early and apparently heritable
CHD, dyslipidemias are much more common than in
the general population. The most prevalent familial dys-
lipidemias associated with CHD are hyperbetalipopro-
teinemia (MIM 144010), hypoalphalipoproteinemia
(MIM 205400, 604091), combined hyperlipidemia
(MIM 144250, 602491), high Lp(a) (MIM 152200),
hypertriglyceridemia (MIM 144600, 145750), and hy-
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percholesterolemia (MIM 143890, 603776) (Genest et
al. 1992).
About 20%–30% of early familial CHD is ascribed
to hypoalphalipoproteinemia, or primary low HDL
cholesterol (HDL-C). Although not initially recognized
as a predisposing dyslipidemia, extensive epidemiolog-
ical work has implicated low HDL-C levels in increased
risk of cardiovascular disease, and low HDL-C is now
considered a true dyslipidemic syndrome (Warnick and
Wood 1995).
About half of the variation in HDL-C levels appears
to be genetically determined (Friedlander et al. 1986;
Hunt et al. 1989; Perusse et al. 1989; Prenger et al.
1992). Defects in several genes are known to cause low
HDL-C, including apolipoprotein AI (ApoAI) (MIM
107680) (Franceschini et al. 1980; Utermann et al.
1982; von Eckardstein et al. 1989; Funke et al. 1991;
Romling et al. 1994; Breslow 1995; Tall and Breslow
1996; Huang et al. 1998; Yamakawa-Kobayashi et al.
1999), apolipoprotein B (ApoB) (MIM 107730) (Pea-
cock et al. 1994), lipoprotein lipase (LPL) (MIM
238600) (reviewed by Fisher et al. 1997), lecithin:cho-
lesterol acyltransferase (LCAT) (MIM 245900) (re-
viewed by Kuivenhoven et al. 1997), and—most re-
cently—ATP-binding cassette transporter 1 (ABC1)
(MIM 205400, 600046) (Bodzioch et al. 1999; Brooks-
Wilson et al. 1999; Rust et al. 1999; Lawn et al. 1999).
However, in aggregate, these known genetic defects ac-
count for only a small proportion of individuals with
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low HDL-C. Some studies have shown association of
HDL-C levels with variations at the hepatic triglyceride
lipase (MIM 151670) (reviewed by Connelly [1998]),
ApoAI/CIII/AIV (MIM 107680) (Cohen et al. 1994),
apolipoprotein CII (MIM 207750) (Bu et al. 1994), apo-
lipoprotein J (MIM 185430) (Nestlerode et al. 1999),
paraoxonase (MIM 168820) (Boright et al. 1998), beta-
glucocerebrosidase (MIM 230800) (Pocovi et al. 1998),
cholesteryl ester transfer protein (CETP) (MIM118470)
(reviewed by Yamashita et al. 1996) and scavenger re-
ceptor BI (SR-BI) (MIM 601040) (Acton et al. 1999)
loci. In most cases, the relevance of these loci to dys-
lipidemias in the general population remains uncertain.
A recent quantitative-trait analysis suggested two loci
controlling HDL-C levels, on chromosomes 8 and 15,
but the underlying genes have not yet been identiﬁed
(Almasy et al. 1999). Thus, the genetic causes of com-
mon low HDL-C remain poorly understood.
This study assesses the evidence for linkage of the
hypoalphalipoproteinemia trait to chromosomal region
11q23 in 105 large Utah pedigrees ascertained with
closely related clusters of early CHD and expanded on
the basis of dyslipidemia. Both two-point and multi-
point linkage analyses were performed. A MOD-score
approach (Clerget-Darpoux et al. 1986) was used to
determine appropriate multipoint phenotype models.
The locus we have detected appears to be distinct from
the ApoAI/CIII/AIV gene cluster.
Material and Methods
Family Recruitment and Development
All the families in this study were ascertained by the
Cardiovascular Genetics Research Clinic (University of
Utah). Most of the families for the CHD project were
identiﬁed through familial aggregation of early-onset
CHD. In collaboration with Intermountain Health Care
(IHC), we used the IHC cardiovascular-disease hospital
discharge records for the years 1990–1995 as a source
of probands. IHC discharge records were screened for
cases of cardiovascular disease, as deﬁned by myocardial
infarction, balloon angioplasty, coronary bypass surgery,
or other explicit symptoms. Early-onset disease was de-
ﬁned as prior to age 55 years for men and prior to age
60 years for women. This screen produced a total of
2,470 potential CHD probands for the 5-year period of
record.
Probands were contacted by telephone and were given
a brief oral questionnaire. Familial history of CHD was
established by the occurrence of disease in relatives of
the proband. All probands with a family history of CHD
were invited to participate in the study by submitting a
detailed medical history and contributing a blood sample
for chemistry analysis and possible DNA testing. Blood
samples were collected after 12–16 hour fasts. Lipids
were measured as described elsewhere (Wu et al. 1989).
Full informed consent was obtained at all stages of the
study.
Probands with family history of CHD who also ex-
hibited dyslipidemia, on the basis of the fasting blood
sample, were subsequently developed into extended ped-
igrees. This expansion did not follow strict sampling
rules. Generally, pedigrees were expanded until a size-
able clustering of dyslipidemic relatives was acquired;
sampling did not extend to all identiﬁed relatives. Since
phenotypic status could only be determined after sam-
pling, based on the lipid proﬁle, affected individuals
could not be preferentially sampled. At early stages of
the analysis, however, affected individuals were prefer-
entially genotyped. In some cases, relatives living out of
state were sampled at local clinics, and the blood samples
were transferred to the central study site for analysis.
Eventually, all sampled members of informative pedi-
grees were genotyped for at least a subset of markers in
the linked region. At later stages of the analysis, some
attempt was made to further extend pedigrees showing
potential linkage to the region, following the best seg-
regating haplotype. Although the primary focus of this
study was low HDL-C, probands with other forms of
dyslipidemia, such as familial combined hyperlipidemia,
were also developed into extended pedigrees. To some
extent, sampling was dependent on available genealog-
ical information. Most pedigrees, however, could be ex-
tended to at least three generations (see Results for a full
description of the pedigree resource).
In addition to the pedigree set identiﬁed from the IHC
coronary-disease probands, a further set of dyslipidemic
pedigrees was made available by the Cardiovascular Ge-
netics Research Clinic at the University of Utah. These
additional pedigrees were developed over the past dec-
ade by use of various ascertainment criteria, including
dyslipidemia, stroke, and hypertension. An attempt was
made to restrict the pedigrees used in this study to those
with dyslipidemia as the major familial phenotype, dis-
regarding in particular those pedigrees with signiﬁcant
morbid obesity. A total of 105 pedigrees were included
in this study.
Phenotype Deﬁnition
Individual phenotypes were encoded as semiquanti-
tative traits. Fasting plasma lipid levels were compared
to the LRC national distribution proﬁles (Lipid Research
Clinics 1980) and were assigned percentiles according
to age and sex by use of the national data set. It would
be inappropriate to use our family data set itself for
determining lipid distributions, since the data set is sub-
ject to a strong ascertainment bias for clustered dysli-
pidemia. Average values were used for those subjects
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with multiple blood draws. On the basis of these per-
centiles, four phenotypic liability classes were deﬁned:
liability class 1, strongly affected, HDL-C  10th
percentile; liability class 2, weakly affected, HDL-C
10th–25th percentile; liability class 3, weakly unaffected,
HDL-C 25th–50th percentile; and liability class 4,
strongly unaffected, HDL-C 1 50th percentile. Individ-
uals with no phenotypic information were coded as un-
known.
Because of the sensitivity of circulating plasma lipid
levels to various confounding factors, some corrections
were applied to the raw percentiles. Diabetic individuals
were classed as weakly affected (liability class 2), re-
gardless of the actual HDL-C concentration at the time
of measurement. Birth control and hormone replacement
in females are both potential confounders; however, the
effects are not thoroughly understood, and, therefore,
no correction was made for these medications. Individ-
uals with hypothyroidism were treated normally if they
were currently taking synthetic thyroid hormone. No
corrections were made for obesity in the subjects or for
alcohol use; signiﬁcant alcohol use is rare in the subjects
comprising this data set.
We chose not to use a quantitative-trait model for
linkage analysis, for several reasons. First and foremost,
the control-population data are presented by the LRC
in the percentile format. In addition, many of the indi-
viduals in the study are on potent medications, whose
quantitative effects on fasting HDL cholesterol are un-
certain. Finally, complicating medical conditions such as
diabetes are also difﬁcult to model quantitatively.
Genetic Markers and Genotyping
Genomic search markers (di-, tri-, and tetranucleotide
repeats) are described in public databases such asMarsh-
ﬁeld and Ge´ne´thon. In some cases, PCR primer se-
quences were moved or modiﬁed to optimize marker
performance. Markers MYR0018, MYR0020, and
MYR0021 are all dinucleotide-repeat markers devel-
oped at Myriad Genetics on the basis of genomic se-
quencing in the region. PCR primers for these markers
are as follows: MYR0018, TTCACAGGGAGCTAT-
GAGAGTA and GTTTCAGGGAGTATTTTAGGT-
AGC; MYR0020, TGGGCTAGTTCATCTTTA-
AGGTAGGT and GTTTAGTGAATACTGAGCAATA-
CATCAAGCT; and MYR0021, GCATAATGTT-
AGCCGTCAATCT and GTTTTGATACTTC-
CTTGGGTCTGTTC. For each marker, the GTTT at
the 5′ end of the second primer is not part of the genomic
sequence but was included to reduce the variability of
addition of nontemplated nucleotides at the 3′ end of
the labeled products (Brownstein et al. 1996).
DNA was prepared from blood samples according to
standard methodologies. PCR products were analyzed
on ABI 377 ﬂuorescent sequencing machines. Of phen-
otyped individuals, 90% (3116 of 3467 in liability clas-
ses 1, 2, 3, and 4) were eventually genotyped, with the
exception of those few individuals for whom DNA ex-
traction following blood draw failed. Genotyping was
not restricted only to affected individuals. All individuals
were genotyped for a central set of 17 of 18 markers
between positions 11.0 and 42.6 on the local genetic
map. For the four markers further removed from the
peak of LOD, a subset of individuals from the most
informative pedigrees was genotyped. Inheritance of all
alleles was veriﬁed by use of the Pedcheck software pack-
age (O’Connell and Weeks 1998). Allele frequencies
were calculated by pooling data from the total set of
genotyped individuals. The large number of independent
pedigrees and married-in spouses in the sample set al-
lowed for an accurate determination of allele frequencies
in this population. Note that, although the genotypes of
related individuals are correlated, the resulting estimated
allele frequencies from the complete data set are, in the
strictest statistical sense, unbiased. Moreover, allele fre-
quencies estimated by use only of the founders (including
spouses) were essentially similar to those estimated by
use of the complete data set.
Building the Genetic Marker Map
The microsatellite markers used in subsequent anal-
yses were mapped by use of the genotyping in the CHD
pedigree set. The 105 large pedigrees were split into 593
independent, CEPH-structured pedigrees (nuclear fam-
ilies with grandparents, where available and typed). This
yielded a mapping resource with 3,916 meioses, which
compares favorably to the resource used by Ge´ne´thon,
comprising 8 large CEPH pedigrees with 186 meioses
(Dib et al. 1996). Initial marker order was obtained from
the Center for Medical Genetics (Broman et al. 1998).
Conﬁdence in order was assessed by use of the “ﬂips5”
option of CRI-MAP (Lander and Green 1987), in which
each quintuple of adjacent markers are permuted and
the likelihood of the map order is calculated. If a dif-
ferent order had a higher likelihood, CRI-MAP was run
with this new order. With the maximum-likelihood or-
der, haplotypes were determined with the “chrompic”
option of CRI-MAP. These haplotypes were used to iden-
tify possible data errors (Litt et al. 1995). After correc-
tion of data errors, the mapping procedure was repeated.
The ﬁnal framework map (table 2) was based on criteria
of a minimum of two crossovers and 11000:1 odds in
favor of the given order of adjacent markers (Litt et al.
1995).
Linkage Analysis
Pairwise linkage analyses were performed with the
FASTLINK modiﬁcations (Cottingham et al. 1993;
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Table 1
Description of the HDL-C Pedigrees Studied
PEDIGREES
NO. OF
INDIVIDUALS
HDL-C LIABILITY CLASS
1 2 3 4 Unknown
Full (n = 105) 4,547 (3,116) 842 (755) 1,009 (898) 702 (631) 914 (830) 1,096 (3)
Split (n = 167) 4,363 (3,057) 836 (753) 997 (886) 681 (615) 883 (802) 966 (1)
NOTE.— Numbers in parentheses are counts of genotyped individuals in each liability class. Most
of the individuals whose phenotypes are unknown were not sampled or genotyped. Liability classes
are deﬁned with respect to the LRC national lipid frequency distribution tables, not according to the
lipid distributions in the data set itself (see Material and Methods).
Schaffer et al. 1994) of LINKAGE (Lathrop and Lalouel
1984; Lathrop et al. 1984, 1986). Multipoint linkage
analyses were performed with MCLINK (Thomas et al.,
in press), which implements a Gibbs sampling, Monte
Carlo, Markov chain algorithm to generate multipoint
inheritance matrices (haplotypes) from the genotyping
data. Phenotype data are then incorporated to evaluate
multipoint LOD scores (mpLOD). Heterogeneity anal-
yses used the admixture test of Smith (1961), in which
(estimated proportion of linked pedigrees) and (es-ˆaˆ v1
timated recombination fraction for the linked pedigrees)
are jointly varied, and a maximum LOD score in the
presence of heterogeneity (HLOD for pairwise LOD) is
calculated. For multipoint data, is not estimated;ˆv1
rather, the map position is considered an independent
variable (mpHLOD).
The rules by which pedigrees were ascertained and
expanded made segregation analysis inappropriate, re-
quiring the speciﬁcation of phenotype models on a more
ad hoc basis. The initial phenotype model assumed a
major gene with dominant mode of inheritance and
modest frequency (.01) and penetrances such that, for
increasing HDL-C concentrations, the penetrance for
gene carriers and the probability of being a gene carrier
decreased. Model optimizations (MOD scores) were
evaluated for mpLOD scores. Five model parameters
were varied, considering only a dominant mode of in-
heritance: the gene frequency and one value in each li-
ability class; this value was the penetrance of the
non–gene carriers for liability classes 1 and 2 (the ﬁrst
penetrance) and the penetrances of the carriers for lia-
bility classes 3 and 4 (the second and third penetrances).
This simpliﬁcation, which essentially varied the pene-
trance ratios between non–gene carriers and carriers,
was possible because each liability class deﬁnes either all
affecteds or all unaffecteds. In all cases, the monotonic
constraints for penetrance and carrier probability de-
scribed for the initial model were maintained. In an at-
tempt to reduce the effect of intrafamilial heterogeneity
in the set of large pedigrees, the pedigrees were also split
into smaller, independent pieces deﬁned by a maximum
of four generations and a minimum of three individuals
in liability classes 1 and 2. This splitting was done with-
out use of linkage evidence. Pedigrees four generations
or fewer in depth were left intact by the splitting
algorithm.
Results
Pedigrees in this study are of northern European descent.
Table 1 describes the ﬁnal pedigree resource used in the
genetic analyses and includes counts of phenotyped and
genotyped individuals in each phenotypic class. Each of
the 105 pedigrees has at least 3 genotyped individuals
whose HDL-C levels place them in liability class 1 or 2,
with an average of 15.7 such individuals per pedigree.
The largest pedigree comprises 224 individuals, 65
whom are affected; the pedigree with the greatest num-
ber of affecteds comprises 177 individuals, 101 affected,
and 97 affected and genotyped. The resource is strongly
enriched for individuals with low HDL-C: 24.3% of
phenotyped individuals have HDL-C levels which place
them in liability class 1 (10% is the expected population
average based on LRC distributions), 53.4% are in li-
ability classes 1 or 2 (25% is the expected population
average). There is also an enrichment for other dysli-
pidemic phenotypes. For example, 38.8% of individuals
in liability class 1 for HDL-C are also in the 95th or
greater percentile for triglyceride levels.
In the ﬁrst stage of the project, linkage to 13 candidate
loci was assessed (apolipoprotein AI/CIII/AIV [MIM
107680], apoAII [MIM 107670], apoB [MIM 107730],
apoCI/CII/E [MIM 107710], apoD [MIM 107740], lec-
ithin:cholesterol acyltransferase [MIM 245900], apoH
[MIM 138700], apolipoprotein regulatory protein I
[MIM 107773], cholesteryl ester transfer protein [MIM
118470], HDL-binding protein [vigilin] [MIM
142695], insulin receptor [MIM 147670], LDL receptor
[MIM 143899], and Lp(a) [MIM 238600]). For each
locus, 1–3 genetic markers were typed in three multi-
generational kindreds (K604, K720, and K610; K610
was subsequently eliminated from the study). Prelimi-
nary evidence was observed only for linkage near the
ApoAI/CIII/AIV gene cluster on chromosome 11q23.
Further sampling in the linked pedigrees and in addi-
tional pedigrees, together with the use of more genetic
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Table 2
Pairwise LOD Scores
MARKER POSITIONa
FULL
PEDIGREES
SPLIT
PEDIGREES
Zmax ˆv Zmax ˆv
D11S1995 .0 .00 .50 .01 .49
D11S1366 4.5 .01 .48 .08 .44
D11S2000 11.0 .12 .47 .11 .47
D11S1998 23.3 .08 .42 .15 .40
D11S924 25.4 1.12 .39 1.37 .37
D11S925 27.6 2.91 .35 3.48 .33
D11S4089 27.8 .77 .42 1.52 .39
D11S4167 29.7 .90 .42 .97 .41
D11S1353 32.5 .95 .41 1.48 .39
MYR0020 33.1 .61 .37 1.27 .34
D11S1328 33.8 .29 .44 .58 .40
MYR0021 34.0 .23 .45 1.53 .37
MYR0018 34.1 .55 .42 1.31 .37
D11S933 35.2 2.07 .37 1.34 .38
D11S4158 35.7 .34 .45 .98 .41
D11S1896 37.1 .48 .41 1.36 .36
D11S934 37.6 .98 .42 1.84 .38
D11S4151 37.8 .46 .43 1.63 .38
D11S4111 39.9 .85 .41 1.16 .39
D11S912 42.6 .97 .39 1.61 .36
D11S1304 51.0 .00 .50 .00 .50
D11S2359 55.2 .07 .45 .05 .43
a Positions are in Kosambi cM relative to
D11S1995, which is actually at 93.1 cM on theMarsh-
ﬁeld chromosome 11 sex-averaged genetic map.
markers, quickly shifted the region of interest distal to
the apolipoprotein gene cluster. The markers used for
this study reﬂect this, with several around the ApoAI/
CIII/AIV cluster, but with a higher density distal. By the
conclusion of the study, 90% of sampled individuals
were genotyped. Because genetic analyses were ongoing
during the extended sampling phase, rather than pre-
senting all intermediate stages only the linkage results
for the ﬁnal data set will be presented here.
Pairwise maximum LOD scores (Zmax), using the in-
itial phenotype model, are shown in table 2. The marker
order corresponds well with published genetic maps
(Broman 1998), although we were able to conﬁdently
order several markers which were previously unordered
and to place the three novel MYR markers in the map.
The highest pairwise Zmax for full pedigrees is 2.91 and
occurs at D11S925. Four pedigrees show linkage to
D11S925 with Zmax 11.0, and 12 pedigrees are linked
between D11S924 and D11S933 (a 9.8-cM region) with
Zmax 11.0 (table 3); the maximum LOD score exhibited
by a single pedigree (K3311) is 2.41 at MYR0021.
K3311 was not one of the original three pedigrees
searched for linkage but was ascertained through a cor-
onary disease sib trio in which all three siblings shared
a haplotype in the region of linkage. Heterogeneity anal-
ysis yielded no evidence for an admixture of linked and
unlinked pedigrees ( ).aˆ = 1
The value of v at which Zmax occurs ( ) is 1.34 forˆv
all markers in the region. This could be the result of
locus heterogeneity, allelic heterogeneity, or model mis-
speciﬁcation. Locus heterogeneity is identiﬁed by the
admixture test if the gene frequency is sufﬁciently small
relative to the pedigree size; that is, there is little intra-
familial heterogeneity caused by multiple loci segregat-
ing within a single pedigree. Because the admixture test
provided no evidence for locus heterogeneity, we split
the pedigrees into four-generation independent pieces to
assess the contribution of intrafamilial heterogeneity.
The pairwise LOD scores for these split pedigrees are
also shown in table 2. Although having only a slight
effect on , and no effect on admixture evidence, theˆv
LOD score attained a signiﬁcant value of 3.48. Fifteen
split pedigrees are linked between D11S924 and
D11S933 with Zmax 11.0, with a single-pedigree max-
imum LOD score of 2.95 for K3311 (table 3).
Multipoint analyses were performed to identify a lo-
calization region and to further investigate phenotype
modeling. The initial phenotype model gave low
mpLOD scores for both full pedigrees and splits: 0.97
and 0.88, respectively, with . Model optimizationaˆ = 1
was performed using mpHLOD as the dependent var-
iable and the entire map interval between D11S1995
and D11S2359 (55.2 cM). The optimized model for the
full pedigrees generated a maximum mpLOD of 3.69
and maximummpHLOD of 4.68 ( ), both at mapaˆ = .68
position 32.5 cM on the region map (ﬁgure 1a). Op-
timization for the split pedigrees yielded a slightly dif-
ferent result (ﬁgure 1b), with maximummpLOD of 3.89
(map position outside of the marker map) and maxi-
mum mpHLOD of 5.19 ( , map position 33.0aˆ = .36
cM). There are two major differences between the initial
phenotype model and the optimized models (table 4);
the optimized models have a higher gene frequency and
have a higher penetrance for non–gene carriers than
carriers in liability class 2; that is, individuals in liability
class 2 are more likely to be non–gene carriers than
carriers.
Phenotype model misspeciﬁcation in the initial model
was identiﬁed by a high at Zmax. To evaluate the op-ˆv
timized models in the same way, pairwise LOD scores
were calculated using these models. For the full pedi-
grees, the highest pairwise Zmax was 2.79, with ;ˆv = .05
split pedigrees had the highest pairwiseZmax = 2.25, with
.21. Heterogeneity analysis yielded (HLOD =ˆ ˆv v = .041
2.82, ) for full pedigrees, and (HLOD =ˆaˆ = .87 v = 01
2.99, ) for the splits. Thus, the models optimizedaˆ = .33
for mpHLOD retained power to detect linkage when
used for pairwise linkage analyses. A further conﬁr-
mation that the optimized models describe the linked
pedigrees is provided by analyzing only those pedigrees
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Table 3
Strongly Linked Pedigrees
Pedigree ID
No.
Affecteda
No.
Phenotyped
No. in
Pedigree
Maximum
LOD in
Regionb
Map Position
of LODc
(cM)
Full pedigrees:
3311 26 124 147 2.41 34.0
1001 9 40 58 1.86 33.1
1277d 17 36 39 1.77 27.6
612d 24 53 63 1.57 35.2
726 15 57 70 1.47 27.8
3526d 15 59 74 1.34 33.1
3216d 9 41 47 1.29 27.6
3101d 12 68 73 1.19 35.2
506 18 113 130 1.08 35.7
794d 4 17 24 1.07 27.6
3437d 6 26 31 1.06 25.4
3565d 7 16 19 1.01 25.4
Split pedigrees:e
331102 22 108 128 2.95 32.5
117302 9 37 39 1.57 34.1
7300102 6 21 28 1.26 25.4
306502 6 21 28 1.26 25.4
348001 5 15 24 1.25 33.1
343401 8 25 31 1.14 25.4
72601 9 30 32 1.11 27.8
a Individuals in liability class 1: HDL-C  10th percentile.
b Maximum pairwise LOD scores between markers D11S924 and D11S933.
c Position of the marker at which the maximum LOD score was found, relative to
D11S1995.
d The split pedigree is identical to the full pedigree.
e The originating full pedigree ID is determined by deleting the last two digits of the
split ID.
identiﬁed as linked. Using the criterion suggested by Ott
(1983) of Zmax 1 0 and considering the entire 55.2-cM
interval, 73 full pedigrees and 110 split pedigrees were
selected. The mpLOD and mpHLOD curves (ﬁgure 1c
and d) for the linked pedigrees show little or no evidence
of heterogeneity near the peak of LOD.
The linkage conﬁdence interval may be determined
from the mpLOD plots in ﬁgure 1. Using the recom-
mendation of Zmax1 by Conneally et al. (1985), the
HDL-C locus maps to 11q23.3 between D11S4167 and
MYR0021 (a 4.3-cM interval) (ﬁgure 1d). This linkage
is at least 10 cM distal to the apoAI/CIII/AIV cluster,
which maps between D11S2000 (11.0 cM in ﬁgure 1)
and D11S1998 (23.3 cM in ﬁgure 1) (Broman et al.
1998), and represents a putative novel locus governing
serum HDL-C concentration.
To assess whether our conclusions regarding region
localization and ApoAI/CIII/AIV exclusion are artifacts
of the use of phenotype models optimized for peak
mpHLOD score, two other optimization strategies were
used. Independently optimizing at each position in the
interval shows that the decrease in mpHLOD on each
side of the peak at position 32.5 cM (ﬁgure 2a and b,
dashed curves) gives nearly identical results as use of
the optimized model optimized at the peak (ﬁgure 1a
and b, dashed curves). To determine whether there is a
phenotype model which indicates linkage to the ApoAI/
CIII/AIV cluster, rather than the peak at 32.5 cM,model
optimization was performed exclusively in the 12-cM
interval deﬁning the ApoAI/CIII/AIV cluster. The model
which yielded the maximum mpHLOD in this interval
was then applied to the entire region. Although there
is some attenuation of the mpHLOD score at the peak
(ﬁgure 2a and b, solid curves), the peak is still at position
32.5 cM and 12 LOD units greater than the maximum
mpHLOD in the ApoAI/CIII/AIV interval.
Discussion
In the present study, we have identiﬁed a putative novel
locus on chromosome 11q23.3 contributing to familial,
low HDL-C. By use of a resource of large, multiplex
Utah pedigrees ascertained through cases of early-onset
CHD, preliminary evidence from a scan of candidate
genes indicated linkage near the ApoAI/CIII/AIV cluster.
Addition of markers, pedigrees, and individuals within
pedigrees localized the linkage to a 4.3-cM interval
between D11S4167 and MYR0021 (0.2 cM distal to
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Figure 1 Multipoint LOD scores for 22 markers in 11q23.3 using phenotype models optimized for mpHLOD. Solid curves, mpLOD
scores; broken curves, mpHLOD scores. Within each panel, the phenotype model used for analysis was the one yielding the peak mpHLOD
score. a, 105 full pedigrees. b, 167 split pedigrees. c, 73 linked, full pedigrees analyzed with the optimized model from a. d, 100 linked, split
pedigrees analyzed with the optimized model from b.
D11S1328), ∼10 cM distal to the ApoAI/CIII/AIV clus-
ter. We found no evidence for linkage directly over this
apolipoprotein gene cluster.
Pairwise linkage results are robust to phenotypic
model misspeciﬁcation (Ott 1977). Under the correct
mode of inheritance, this misspeciﬁcation may cause a
loss of power to detect linkage and an inﬂated , butˆv
the type I–error rate is unchanged. On the basis of the
observation that to every marker in the localizationˆv
region was 1.3, the initial phenotype model was not
accurately speciﬁed. Nonetheless, a signiﬁcant LOD
score of 3.0 was nearly achieved by full pedigrees (2.91)
and was exceeded by splits (3.48). Applying a two-test
Bonferonni correction to these scores still yields a sig-
niﬁcant LOD score of 3.19 and is clearly conservative
in that the data sets are not independent; many of the
“split” pedigrees are identical to the full pedigrees.
Multipoint linkage results, on the other hand, are not
robust to model misspeciﬁcation (Risch and Giuffra
1992); the inﬂated in pairwise analysis is seen as aˆv
negative mpLOD score at the actual locus position. To
use multipoint results to localize the locus identiﬁed by
pairwise analyses, we performed model optimization by
maximizing the mpHLOD. We chose the heterogeneity
measure (rather than the mpLOD) because an assump-
tion of was unrealistic for a phenotype likely toa = 1
be affected by multiple loci. Although the statistical
characteristics of the mpHLOD are not as well behaved
as those of the HLOD, our goal at this stage was not
to demonstrate signiﬁcant linkage but to ﬁnd a phe-
notype model that allows locus localization. We chose
to use a phenotype model based on a small number of
liability classes (four HDL-C levels, standardized to age/
sex population norms) rather than a quantitative model
based on two or three Gaussian distributions (see Ma-
terial and Methods for explanation). The models de-
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Table 4
Phenotype Models
MODEL AND LIABILITY CLASS
PENETRANCE OF GENOTYPE
AA Aa aa
Initial:a
1 .025 .500 .500
2 .150 .350 .350
3 .200 .800 .800
4 .200 .800 .800
Optimized for full pedigrees:b
1 .079 .500 .500
2 .429 .350 .350
3 .200 .654 .654
4 .200 .654 .654
Optimized for split pedigrees:c
1 .074 .500 .500
2 .577 .350 .350
3 .200 .771 .771
4 .200 .771 .771
a Frequency of allele a = .010.
b Frequency of allele a = .487.
c Frequency of allele a = .349.
rived from mpHLOD optimization met our require-
ments for suitability: (1) improved multipoint scores
(mpHLOD of 4.68 for full pedigrees, 5.19 for split ped-
igrees), (2) multipoint LOD traces that did not exclude
the linkage region as deﬁned by pairwise analyses, and
(3) pairwise analyses with and . When theˆ ˆv = 0 a ! 11
optimized models and a Zmax1 criterion are used, a
localization region of 4.3 cM is found. This region is
consistent between full pedigrees and splits and between
the complete data set and linked pedigrees.
Support that this linkage and the ApoAI/CIII/AIV
cluster are distinct is provided by a number of obser-
vations. The pairwise linkage results show no evidence
of linkage to the two markers ﬂanking the cluster,
D11S2000 and D11S1998. Localization scores, based
on optimized models and either full pedigrees or split
pedigrees, exclude the region deﬁned by the two cluster-
ﬂanking markers by at least 4 LOD units. The shape of
the mpHLOD curve is quite similar whether the gen-
erating phenotype model was derived by maximizing
the peak mpHLOD score or was independently derived
at each position; in both cases, the ApoAI/CIII/AIV
interval is excluded relative to the peak between
D11S4167 and MYR0021. And, even if the mpHLOD
analysis model is optimized only in the ApoAI/CIII/AIV
interval, this peak is strongly favored. Finally, we have
screened all exons of the apolipoprotein AI gene by
direct sequencing in a search for mutations, using sam-
ples from a set of the linked pedigrees (including K3311,
the most strongly linked). No potential mutations were
observed (S. Wagner, personal communication).
It is important to note that phenotype models devel-
oped by maximizing the pairwise HLOD did not meet
the requirements of a suitable localization model, yield-
ing inappropriate values of and . The maximumˆ ˆv a1
HLOD, maximizing each marker separately, was found
at D11S925, the peak of the pairwise LOD scores. For
full pedigrees , and (HLOD = 3.93); forˆ ˆv = .38 a = 11
splits, and (HLOD = 4.63).ˆ ˆv = .35 a = 11
A four–liability class phenotype is not the most par-
simonious model, in terms of number of liability classes.
Table 4 shows that the optimized models treat liability
classes 3 and 4 identically. The number of liability clas-
ses in the optimized models may be reduced further with
little loss in power. A one–liability class model, in which
all phenotyped individuals in liability class 1 are con-
sidered affected and all other phenotyped individuals
are considered unaffected, yields mpHLOD scores of
4.23 ( ) for full pedigrees and 4.52 ( ) forˆ ˆa = .65 a = .32
splits at the same map position as the four–liability class
model.
Several linkages have been proposed near 11q23 by
means of phenotypes potentially related to low HDL-
C. Evidence for linkage to 11q23 was observed in the
Finnish study of familial combined hyperlipidemia (Pa-
jukanta et al. 1999), speciﬁcally to marker D11S4464,
by means of either simple high total cholesterol or apoB
levels. This marker, although not shown on our genetic
map, is within the region of maximum linkage reported
in this study, on the basis of physical and genetic map-
ping (S. Wagner, personal communication). The Finnish
linkage to 11q23, with a maximum LOD score of 1.8,
did not achieve suggestive statistical signiﬁcance (LOD
1.9) (Lander and Kruglyak 1995). In light of our results,
it should potentially be reevaluated, perhaps with HDL-
C concentration as a phenotype.
Two genomic scans have identiﬁed suggestive linkages
near 11q23 by use of measures of obesity as a pheno-
type. Hanson et al. (1998) found their strongest linkage
to body mass index (BMI) and type II diabetes among
Pima Indians between genetic markers D11S4464 and
D11S912, coinciding with the peak of linkage reported
in this study. Likewise, Jaquish et al. (1998) found the
strongest linkage to BMI in the Framingham study be-
tween markers D11S1998 and D11S912.
Because there is a known relationship between obesity
and dyslipidemia, we felt that it was important to test
whether our linkage was a direct result of an obesity
phenotype. Therefore, we reexamined our pedigrees for
any relationship between obesity and hypoalphalipo-
proteinemia and for linkage of obesity to our genetic
markers. A number of lines of evidence indicate that
obesity is not responsible for the low HDL-C linkage
reported here. (1) There are relatively few obese indi-
viduals in the data set: 200 with body mass index (BMI)
135 (morbidly obese), representing 6.3% of the indi-
viduals with height/weight information; and 215 with
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Figure 2 Comparison of mpHLOD scores for phenotype models optimized for the region containing the ApoAI/CIII/AIV cluster and
models optimized independently at each map position. Solid curves were derived using the phenotype model yielding the maximum mpHLOD
score in the cluster region, broken curves are mpHLOD scores independently maximized. a, 105 full pedigrees. b, 167 split pedigrees.
BMI between 32 and 35 (moderately obese), repre-
senting 6.7%. (2) The correlation between BMI and
HDL-C level is low ( ). (3) There is little evi-r = .20
dence of linkage in this region when our data set and
an obesity phenotype are used. A qualitative analysis
model (likely gene carrier if BMI 1 35) yielded pairwise
maximum HLODs of 0.34 for full pedigrees and 0.31
for splits. A bimodal quantitative model (Adams et al.
1993) yielded HLODs of 0.91 for both full pedigrees
and splits. Such LOD scores are below a suggestive sig-
niﬁcance level. (4) None of the pedigrees which gave
linkage evidence (LOD 1 0.5) with an obesity phenotype
gave linkage evidence based on HDL-C levels. Although
a single gene may be responsible for the obesity phe-
notype reported by others and for the low HDL-C phe-
notype reported here, our results offer no support for
this hypothesis and are consistent with independent loci.
In contrast to these results, three genomic scans for
loci regulating HDL-C levels failed to show linkage to
our region. Almasy et al. (1999) report linkages on chro-
mosomes 8 and 15 among Pima Indians, Imperatore et
al. (1998) to chromosome 3 among Pima Indians, and
Cupples et al. (1998) to chromosome 6 among Fra-
mingham study participants. It is difﬁcult to interpret
the lack of concordance among these studies, given the
differences in methodology and in the populations being
studied.
On the other hand, numerous studies have attempted
to examine association or linkage between genetic
markers in the apolipoprotein AI/CIII/AIV cluster and
dyslipidemia. Some investigators report ﬁnding strong
association to this region (Wojciechowski et al. 1991;
Dammerman et al. 1993; Cohen et al. 1994); others
ﬁnd weaker association (Kaprio et al. 1991; Peacock et
al. 1994; Kamboh et al. 1999), whereas some ﬁnd little
or no association (Mahaney et al. 1995; Wijsman et al.
1998). Clearly, mutations in the apolipoprotein AI gene
itself have potential for predisposition to dyslipidemia
(Breslow 1995; Tall and Breslow 1996; Yamakawa-Ko-
bayashi et al. 1999). It remains uncertain whether the
other reported associations involve causal genetic var-
iants within this apolipoprotein gene cluster itself. Po-
tentially, some of these other associations might be due
to variations at the locus reported in this study. Mo-
lecular cloning in the linked region described in this
report—and, ultimately, identiﬁcation of the predispos-
ing gene—should permit clariﬁcation of these effects.
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